The Role:
We are seeking a highly collaborative and hands-on Senior Director / Executive Director, Investor Relations to help build and scale our investor relations function as a newly public biotechnology company. This role will serve as a close partner to the CFO and work cross-functionally with Strategy, Corporate Communications, Legal, Finance, Technology and R&D to translate our science, pipeline strategy, wet lab capabilities, and machine learning technology into clear, credible, and consistent communications for investors and analysts.
This role requires exceptional writing and executive communication skills, strong scientific curiosity and fluency, and the ability to operate with discipline and urgency in a public-company environment. The successful candidate will be comfortable drafting important external materials, building repeatable processes, and responding to investor and analyst questions with accuracy and strong judgment. While this role will not be expected to solely lead investor dialogue initially, it is designed to grow into increased external engagement over time.
This role is based in Somerville, MA and is expected to be onsite five days a week.
Here's how you will contribute:
Build and run a high-performing IR operating cadence
-
Help establish scalable IR processes as a newly public company, including a disciplined quarterly calendar integrating close, filings, earnings releases and major milestones.
-
Drive materials discipline and version control across all investor-facing content, ensuring consistent messaging across decks, scripts, Q&A, press releases, and web postings.
-
Partner with Finance, Legal, and Communications to adhere to public-company guidelines and ensure strong execution under tight timelines.
Own drafting and development of investor-facing materials
-
Draft and maintain key corporate and investor materials, including the corporate overview deck and conference presentations
-
Support drafting of earnings-related communications, including press release language, earnings scripts, if relevant, and Q&A books in CEO/CFO/CSO/CMO/CTO voices.
-
Translate complex experimental results and technical platform capabilities into clear “so what” investor language, backed by precise proof points and appropriate messaging boundaries.
Support investor and analyst communications and responsiveness
-
Serve as a key point person (with CFO oversight) for inbound investor and analyst questions, coordinating internally to source accurate answers and ensure consistent messaging.
-
Prepare executives for investor and analyst engagements through pre-briefs, talking points, anticipated questions, and rehearsal support.
-
Support analyst onboarding and teach-ins, initiation coordination, and follow-up communication in partnership with the CFO, Strategy, and Communications.
Drive conference preparation and execution
-
Plan and execute conference preparation across content, logistics, rehearsal, and follow-up, ensuring high-quality materials and consistent messaging.
-
Support meeting strategy and tracking: capture investor feedback, maintain meeting notes discipline, and summarize themes for internal leadership.
Deepen scientific and platform fluency to strengthen the equity story
-
Develop a working understanding of our pipeline, experimental capabilities in the wet lab, and core machine learning platform to accurately represent our work externally.
-
Build strong internal relationships across R&D, translational, clinical, and ML/data science teams to rapidly synthesize updates and translate them into investor-ready messaging.
-
Partner with the Strategy team to ensure the external narrative remains aligned with corporate priorities, milestones, and capital allocation framing.
Support issues management and rapid response
-
Help prepare rapid-response materials for market-moving moments (data releases, competitive headlines, media coverage), including draft statements, updated Q&A, and internal alignment plans.
-
Maintain strong disclosure discipline and partner closely with Legal and Communications to ensure Reg FD-aligned messaging.
The Ideal Candidate will have:
-
10+ years of experience in investor relations, healthcare equity research, corporate communications, or a closely related capital markets role; biotech experience required.
-
Demonstrated excellence in writing and editing, including experience drafting investor materials, scripts, Q&A, and public-company communications.
-
Strong ability to learn complex science and technology quickly and communicate it clearly to external audiences.
-
Experience supporting the public-company cadence (earnings, conferences, investor communications); newly public / IPO experience strongly preferred.
-
Strong cross-functional execution skills, including stakeholder management, calendar discipline, process building, and version control.
-
High judgment, attention to detail, and comfort operating with confidentiality and disclosure sensitivity.
Strongly Preferred
-
Scientific training (degree or equivalent experience in biology, chemistry, bioengineering, computational biology, or a related discipline).
-
Experience with technology-enabled biotech narratives, including machine learning-driven discovery or platform companies.
-
Prior experience working closely with CFO/CEO leadership in high-stakes communication settings.
The ideal candidate is:
-
A clear, persuasive communicator with exceptional writing skills and the ability to craft content in an executive voice
-
Highly curious and motivated to learn both the science and the machine learning platform deeply
-
Collaborative with a focus on shared success and strong cross-functional relationship-building instincts
-
Structured, disciplined, and able to build repeatable processes in a fast-moving environment
-
Comfortable operating in ambiguity and rapidly producing high-quality drafts under time pressure
-
Energized by working at the intersection of biotech and advanced technology in a mission-driven organization
#LI-KD1
About Generate:Biomedicines
We are a clinical-stage generative biology company pioneering the AI revolution in drug design and development. We are advancing a new approach to drug creation—one grounded in the ability to design proteins with defined biological intent. By integrating machine learning with large-scale experimentation, this approach aims to reduce the uncertainty, time, and cost associated with developing protein-based medicines.
Founded in 2018, we are advancing a growing pipeline of clinical and preclinical programs across multiple disease areas and protein modalities. By unifying computational design and clinical development within a single operating model, we translate this approach into clinical-stage programs and are leading a shift from traditional drug discovery toward systematic drug generation.
At Generate:Biomedicines, we collaborate across disciplines in new ways to invent and innovate. We bring diverse perspectives to a shared goal of delivering better medicines to patients in need, faster, guided by our values and leadership behaviors.
Generate:Biomedicines is committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.
Recruitment & Staffing Agencies: Generate:Biomedicines does not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to Generate:Biomedicines or its employees is strictly prohibited unless contacted directly by the Company’s internal Talent Acquisition team. Any resume submitted by an agency in the absence of a signed agreement will automatically become the property of Generate:Biomedicines and the Company will not owe any referral or other fees with respect thereto.